Survival in advanced-stage ovarian carcinoma with high VEGF-A expression after addition of bevacizumab. Results from the German ICON7 patient cohort

ESGO eAcademy, Stefan Kommoss, 343681

Efficacy of niraparib by timing of Surgery and residual disease: Post-hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 study

ESGO eAcademy, Roisin O’Cearbhaill, 343679

Impact of co-medication on survival in patients with ovarian cancer - Analysis of 4 prospective trials of the AGO-OVAR and ENGOT/GCIG collaborators

ESGO eAcademy, Dominik Denschlag, 343677

Survival in advanced stage epithelial ovarian cancer patients with cardiophrenic lymphadenopathy who underwent cytoreductive surgery: Meta-analysis

ESGO eAcademy, Malika Kengsakul, 343675

QIs on lymph node staging

ESGO eAcademy, Jan Persson, 343672

QIs related to patient management and to surgical performance in general

ESGO eAcademy, Cagatay Taskiran, 343671

Scientific session 5: ESGO quality indicators in endometrial cancer surgery - Q&A

ESGO eAcademy, Jan Persson, 340721

Identifying truly „actionable“ alterations: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)

ESGO eAcademy, Cristiana Sessa, 340718

Q&A - State of the art 2: Precision medicine in gynaecological oncology

ESGO eAcademy, Cristiana Sessa, 340717

Does platinum rechallenge have a role in the management of endometrial cancer?

ESGO eAcademy, Faculty / Presenters, 340713

Scientific session 3: Prehabilitation and enhanced recovery in gynaecological oncology - Q&A

ESGO eAcademy, Faculty / Presenters, 340704

KORE Innovation trial

ESGO eAcademy, Jalid Sehouli, 340703

State of the art 1: Cervical cancer screening in the era of HPV testing - Q&A

ESGO eAcademy, Faculty / Presenters, 340696

Scientific session 4: Immune checkpoint inhibitors in ovarian cancer - lessons learnt and the road ahead - Q&A

ESGO eAcademy, Faculty / Presenters, 340710

Balance oncological and reproductive outcomes when treating cervical disease - 2020 ESGO-EFC Terminology for cone dimensions

ESGO eAcademy, Maria Kyrgiou, 340695

Implementation of an ERAS prehabilitation program

ESGO eAcademy, ESTER MIRALPEIX, 340702

Challenges and perspective for immunotherapy combinations in ovarian cancer

ESGO eAcademy, Christian Marth, 340709

Reduction in patient morbidity in an ERAS program

ESGO eAcademy, Stephanie Schneider, 340701

HPV screening and triage: ESGO-endorsed kits to be used

ESGO eAcademy, Marc Arbyn, 340694

Immunotherapy in ovarian cancer: from biological findings to clinical trials

ESGO eAcademy, Sandro Pignata, 340708

Cervical cancer elimination: A 100-year-old dream is becoming a reality

ESGO eAcademy, Murat Gultekin, 340693

Overall patient outcomes in ERAS gynaecologic oncology

ESGO eAcademy, Pedro Ramirez, 340700

Scientific session 1: Ultrasound session - Q&A

ESGO eAcademy, Faculty / Presenters, 340682

Scientific session 2: Challenges in surgical, radio-therapeutic and medical treatment of obese patients - Q&A

ESGO eAcademy, Faculty / Presenters, 340689

Preoperative diagnosis of uterine fibroids and sarcomas

ESGO eAcademy, Dirk Timmerman, 340681

Effect of body mass index on the election and effectiveness of medical treatment of gynaecologic cancers

ESGO eAcademy, Shannon Westin, 340688

Cervical cancer staging (live scan)

ESGO eAcademy, Daniela Fischerova, 340680

Radiotherapy as a safe and effective curative treatment in the patients with morbid obesity

ESGO eAcademy, Elzbieta van der Steen-Banasik, 340687

Should we tailor the standard surgical treatment in obese patients?

ESGO eAcademy, Nadeem R. Abu-Rustum, 340686

KEYNOTE-826: Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for persistent, recurrent, or metastatic cervical cancer

ESGO eAcademy, Nicoletta Colombo, 343660

Randomised Phase II BGOG/ENGOT-cx1 study of paclitaxel-carboplatin with or without nintedanib in first-line recurrent or advanced cervical cancer

ESGO eAcademy, Ignace Vergote, 343662

Results of the Avoiding Late Diagnosis of Ovarian Cancer (ALDO) Project; a pilot national surveillance program for BRCA mutation-carriers

ESGO eAcademy, Adam Rosenthal, 343664

Results of NSGO-OV-UMB1/ENGOT-OV30 study: A phase II study of durvalumab and oleclumab in patients with relapsed ovarian cancer (OC)

ESGO eAcademy, Faculty / Presenters, 343666

Session 1 | Psychosocial distress in cancer patients

ESGO eAcademy, Joachim Weis, 346428

Session 1 | Coping and adjustment with cancer

ESGO eAcademy, Joachim Weis, 346429

Session 1 | Introduction to Psycho-Oncology P-O care system

ESGO eAcademy, Joachim Weis, 346427

Session 2 | Psycho-oncological interventions - Part I

ESGO eAcademy, Joachim Weis, 346430

Session 2 | Psycho-oncological interventions - Part II

ESGO eAcademy, Joachim Weis, 346431

Session 2 | Psycho-oncological interventions - Part III

ESGO eAcademy, Joachim Weis, 346432

Session 2 | Psycho-oncological interventions - Part IV

ESGO eAcademy, Joachim Weis, 346433

Psychooncology e-Module

ESGO eAcademy, Joachim Weis, 346434

Evaluation Form & Certificate

ESGO eAcademy, Faculty / Presenters, 346377

Inspiring leaders interview with prof. Andreas du Bois

ESGO eAcademy, Luis Chiva, 345839

How to avoid peritoneal tumor spillage during total abdominal hysterectomy in uterine cancers with cervical invasion?

ESGO eAcademy, Gwenael Ferron, 346307

Radical hysterectomy in early cervical cancer in Europe: characteristics, outcomes and evaluation of ESGO quality indicators

ESGO eAcademy, Felix Boria, 346306

Principles of urinary reconstruction in gynecologic oncology

ESGO eAcademy, Faculty / Presenters, 345842

Principles of urinary reconstruction in gynecologic oncology

ESGO eAcademy, Faculty / Presenters, 336197

Registration form

ESGO eAcademy, Faculty / Presenters, 336196

What do the patients with ovarian cancer expect from us? An anthropological perspective

ESGO eAcademy, Luis Chiva, 344919

Complementary anti-cancer therapies: caveats and benefits

ESGO eAcademy, Jalid Sehouli, 344918

Regimens and novel aspects of oncologic follow up

ESGO eAcademy, Dimitros Tsolakidis, 344917

Quality of life metrics after radical debulking surgery

ESGO eAcademy, Sudha Sundar, 344916

Reconstructive bowel surgery techniques for ovarian cytoreduction

ESGO eAcademy, Gwenael Ferron, 344915

Quality assurance programs and metrics in Ovarian cancer surgery

ESGO eAcademy, Christina Fotopoulou, 344914

Value of surgery in relapsed epithelial ovarian cancer

ESGO eAcademy, Andreas du Bois, 344913

COVID-19 and Ovarian cancer – a game changer

ESGO eAcademy, Dimitrios Haidopoulos, 344912

Low grade and mucinous histology an overview

ESGO eAcademy, Philippe Morice, 344911

Sentinel node concepts in ovarian cancer

ESGO eAcademy, Fagotti Anna, 344910

Anaesthetic considerations and fragility scores for patients’ stratification prior to surgery

ESGO eAcademy, Emmanuel Stamatakis, 344909

Novel screening concepts in ovarian cancer

ESGO eAcademy, John Krell, 344908

Imaging modalities in ovarian cancer diagnosis

ESGO eAcademy, Dirk Timmerman, 344906

ENYGO LiFE Report - 13th edition

ESGO eAcademy, Charalampos Theofanakis, 344685

HRD testing and PARP Inhibitors e-Module

ESGO eAcademy, Faculty / Presenters, 341920

Session 1: PARP inhibitors | PARP in recurrent disease

ESGO eAcademy, Frederik Marmé, 341921

Session 1: PARP inhibitors | First line

ESGO eAcademy, Domenica Lorusso, 341922

Session 1: PARP inhibitors | Future combinations

ESGO eAcademy, Iain McNeish, 341923

Session 2: HRD Testing | HRD and genetic testing

ESGO eAcademy, Rowan Miller, 341924

Session 2: HRD Testing | How HRD and genetic testing might be applied to using PARP inhibitors

ESGO eAcademy, Alejandro Fidalgo, 341925

Session 2: HRD Testing | Other ways of looking at phenomenon of HRD - perhaps the European (ENGOT) initiative on HRD assays?

ESGO eAcademy, Alexandra Leary, 341926

Role of adjuvant radiation therapy after radical hysterectomy in patients with stage IB cervical carcinoma and intermediate risk factors

ESGO eAcademy, Dimitrios Nasioudis, 342897

Webinar 5: Tools for Successfull Scientific Presentations

ESGO eAcademy, Pedro Ramirez, 337405

Webinar 3: Steps to Peer Review Process

ESGO eAcademy, René Pareja, 337403

Webinar 2: Structuring a Scientific Manuscript

ESGO eAcademy, Christina Fotopoulou, 337402

Webinar 1: Strategies for Scientific Publication and Literature Analysis

ESGO eAcademy, Pedro Ramirez, 337401

Complication Management: Common complications of upper abdomen surgery

ESGO eAcademy, Sascha Santosh Chopra, 337200

A Walk in the PARP: Remodeling the Landscape of Newly Diagnosed Advanced Ovarian Cancer - Spanish

ESGO eAcademy, Faculty / Presenters, 336699

A Walk in the PARP: Remodeling the Landscape of Newly Diagnosed Advanced Ovarian Cancer - Italian

ESGO eAcademy, Faculty / Presenters, 336698

A Walk in the PARP: Remodeling the Landscape of Newly Diagnosed Advanced Ovarian Cancer - German

ESGO eAcademy, Faculty / Presenters, 336697

Walk in the PARP: Remodeling the Landscape of Newly Diagnosed Advanced Ovarian Cancer - French

ESGO eAcademy, Faculty / Presenters, 336696

Assessment of anastomotic perfusion using indocyanine green fluorescence angiography following bowel resection for gynecologic malignancies: an instructional surgical video 

ESGO eAcademy, Taymaa May, 336693

Introduction to GO training and the new ESGO eLogbook Webinar

ESGO eAcademy, Faculty / Presenters, 336570

Evaluation Form & Certificate

ESGO eAcademy, Faculty / Presenters, 333814

Complication Management Urogenital Tract

ESGO eAcademy, Joerg Neymeyer, 336079

Immediate lymphatic reconstruction: the time is right to prevent lymphedema following lypmhadenectomy for vulvar cancer

ESGO eAcademy, Faculty / Presenters, 336069

Session 5: Molecular Tumour Boards

ESGO eAcademy, Faculty / Presenters, 333245

Endocervical adenocarcinoma – clinical caseSilva pattern-based personalized risk stratification system for clinical implementation Case study 1 (interactive)

ESGO eAcademy, Andrei Pletnev, 333243

Session 5: Molecular Tumour Boards | DAY 2 - July 2nd, 2021 - 12:05-13:10 CEST

ESGO eAcademy, Faculty / Presenters, 333238

Introduction

ESGO eAcademy, Faculty / Presenters, 333240

How to establish Molecular Tumour Boards in Clinical Practice (interactive)

ESGO eAcademy, Tjalling Bosse, 333241

Immunotherapy and Immuno-targeting HPV as a therapeutic strategy

ESGO eAcademy, Fagotti Anna, 333236

Session 4: Cervical and Vulvar Cancer

ESGO eAcademy, Faculty / Presenters, 333237

Vaccination strategies and role in the prevention and treatment of (cervical and) vulvar cancer

ESGO eAcademy, Elmar Joura, 333235

Session 4: Cervical and Vulvar Cancer | DAY 2 - July 2nd, 2021 - 10:50-12:05 CEST

ESGO eAcademy, Faculty / Presenters, 333231

Introduction

ESGO eAcademy, Faculty / Presenters, 333233